Secondary progressive multiple sclerosis

1 paper

Humans1

Trial sponsors

Zenas BioPharma
Company1 trialPhase 3990 people
AB Science
Company1 trialPhase 3656 people
Indapta Therapeutics
Company1 trialPhase 134 people
University College London
2 trialsPhase 31,004 people
University College London (UCL) Cancer Institute
2 trialsPhase 31,004 people
University of California Los Angeles
2 trialsPhase 287 people
Imperial College London
1 trialPhase 2140 people
University Hospital, Antwerp
1 trialPhase 2120 people

Latest

1 in 12 months

Journal of the Neurological Sciences31 Mar

Clocks out of sync: Increased epigenetic aging variability in multiple sclerosis

Cross-sectional study in peopleMultiple sclerosis